ACCENDRA HEALTH INC/VA/ 8-K

What Happened
On May 11, 2026, Accendra Health, Inc. announced it entered a Commitment and Consent Letter with holders of its outstanding 2029 and 2030 notes and its lenders to pursue a package of transactions to restructure its debt. The plan calls for issuing $326.25 million of newly issued 9.000% Senior Secured First Lien Notes due 2032 (the “First Lien Notes”), offering newly issued 9.750% Senior Secured Second Lien Notes due 2033 (the “Second Lien Notes”) in exchange for the company’s existing 4.500% notes due 2029 and 6.625% notes due 2030, and soliciting consents to amend the existing note indentures to remove many covenants and defaults. The filing also furnishes an investor presentation and contemplates a new $300.0 million revolving credit facility.

Key Details

• Commitment Letter date: May 11, 2026; termination on final closing or June 30, 2026.
• New-money First Lien Notes: $326.25 million aggregate principal; Backstop Parties agreed to buy $261.0M at par and up to an additional $65.25M (if unsold), with a 3.50% cash backstop fee.
• Exchange structure: eligible holders of the 2029 and 2030 notes will be offered First Lien and/or Second Lien Notes in exchange; Consent Solicitations seek amendments to eliminate many affirmative/negative covenants and certain events of default in the existing indentures.
• New Revolving Credit Facility: Commitments to provide a $300.0M revolver due 2030 (subject to customary conditions); Term B‑1 Term Loan lenders agreed to consent to certain waivers and covenant changes tied to the Transactions, including treatment of proceeds from certain $400.0M asset sales and intercreditor amendments.
• Use of proceeds: proceeds from the New Money Notes and cash on hand expected to repay borrowings under the Term “A” facility and the existing revolving credit facility.

Why It Matters
This is a material debt‑restructuring step: Accendra is replacing unsecured or existing debt with higher‑priced secured first‑ and second‑lien notes and seeking to relax covenant and default provisions, which could improve near‑term liquidity and flexibility but changes the company’s capital structure and priority of claims. The backstops and committed $300M revolver reduce financing risk for the plan, but investors should note the substantially higher interest rates (9.0% and 9.75%) and the shift to secured debt. The company’s investor presentation was also furnished with the filing for more details.